NASDAQ$HOLX

Hologic Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Revenue declined due to Cynosure divestiture, but organic revenue increased, and the company posted positive GAAP and non-GAAP EPS.

Hologic's second quarter revenue decreased by 7.6% due to the Cynosure divestiture, but organic revenue increased by 0.5%. The company reported GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.57. Hologic is also introducing a second high-throughput Coronavirus test for its Panther® platform.

  • Second quarter revenue decreased 7.6% due to Cynosure divestiture, 7.1% in constant currency.
  • Organic revenue increased 0.5%, 1.1% in constant currency.
  • Company posted GAAP diluted EPS of $0.36, non-GAAP diluted EPS of $0.57.
  • Company to introduce second high-throughput Coronavirus test for Panther® Platform.

Headline financials

Total Revenue

$756M

Previous: $818M-7.6%
EPS (adj)

$0.57

Previous: $0.58-1.7%
GAAP Gross Margin

52.3%

No prior period
Non-GAAP Gross Margin

61.0%

No prior period
Operating Margin

20.6%

No prior period
Non-GAAP Operating Margin

31.5%

No prior period
Net Margin

12.5%

No prior period
Non-GAAP Net Margin

20.0%

No prior period
Capital Expenditures

-$29.6M

Previous: -$23M-28.7%
Free Cash Flow

$202M

Previous: $215M-6.1%
Net Income

$94.8M

Previous: -$273M+134.8%
Operating Income

$156M

Previous: -$323M+148.4%
Gross Profit

$396M

Previous: $42.4M+833.5%
Cash & Equivalents

$800M

Previous: $401M+99.5%
Total Assets

$6.82B

Previous: $6.53B+4.5%
Stock-Based Comp

$15.7M

Previous: $17.5M-10.3%

Revenue & EPS history

Hologic · Revenue · Quarterly

$756M

Q2 2020-7.6%vs Q2 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Hologic · $818M total across 3 segments · Q2 2020

  • Diagnostics
    $319M
  • Breast Health
    $308M
  • Molecular Diagnostics
    $191M+13.6%

Forward guidance

Hologic expects the COVID-19 pandemic to have a significant negative impact on its future revenue and operating income, especially in the third quarter of fiscal 2020 and withdrew its financial guidance for the second quarter and full year 2020.

Headwinds

  • COVID-19 pandemic is expected to have a significant negative impact on future revenue.
  • COVID-19 pandemic is expected to have a significant negative impact on operating income.
  • The scope and duration of the COVID-19 pandemic are uncertain.
  • Financial guidance for the second quarter of fiscal year 2020 was withdrawn.
  • Financial guidance for the full year 2020 was withdrawn.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

-0.5%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

49%

35 / 72 earnings

Positive

+12.3%

Q3 2020

Best reaction

-11.4%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-0.6%+0.7%
Q4 2025+0.1%+0.1%+0.9%
Q3 2025+2.8%+4.4%+3.3%
Q2 2025-5.6%-3.2%+8.5%
Q1 2025-10.1%-11.4%-11.3%
Q4 2024-4.3%-4.3%-6.6%
Q3 2024+4.9%+6.4%+2.2%
Q2 2024+0.3%-0.2%-3.3%
Q1 2024-2.7%-0.4%-1.1%
Q4 2023+5.7%+5.4%+0.1%
Q3 2023-5.1%-5.9%-5.4%
Q2 2023-2.4%-2.6%-8.3%
Q1 2023+3.8%+3.6%-1.1%
Q4 2022+10.8%+12.4%+13.8%
Q3 2022+1.0%+1.3%-3.4%
Q2 2022+1.2%+3.4%+9.8%
Q1 2022+4.0%+3.8%+2.4%
Q4 2021-3.3%-5.9%-0.3%
Q3 2021+2.3%+5.0%+9.7%
Q2 2021-9.1%-9.9%-13.4%
Q1 2021+1.7%+11.2%-3.3%
Q4 2020+6.6%-5.0%+1.7%
Q3 2020+12.3%+14.8%-2.8%
Q2 2020+2.9%+2.6%+8.9%
Q1 2020-0.7%-1.8%-13.7%
Q4 2019-4.0%+8.8%+10.3%
Q3 2019-1.3%-6.5%-4.1%
Q2 2019-0.1%+0.7%-5.1%
Q1 2019+0.6%-0.5%+8.6%
Q4 2018+4.9%+1.2%+3.7%
Q3 2018-3.5%-1.9%-7.5%
Q2 2018-6.9%-6.8%-3.9%
Q1 2018-6.7%-6.6%-2.2%
Q4 2017+0.4%+2.9%+8.1%
Q3 2017-9.3%-11.3%-12.5%
Q2 2017-4.3%-5.1%-2.0%
Q1 2017-2.6%-2.9%+1.8%
Q4 2016+4.3%+8.5%+6.3%
Q3 2016+3.9%+5.8%+5.3%
Q2 2016-10.0%
Q1 2016-9.2%
Q4 2015+0.6%
Q3 2015+8.6%
Q2 2015+2.1%
Q1 2015+5.1%
Q4 2014-1.7%
Q3 2014+2.1%
Q2 2014+8.1%
Q1 2014-5.9%
Q4 2013-6.9%
Q3 2013-0.2%
Q2 2013+0.1%
Q1 2013-4.1%
Q4 2012-0.3%
Q3 2012-0.4%
Q2 2012-11.4%
Q1 2012+5.2%
Q4 2011-4.0%
Q3 2011-3.9%
Q2 2011-0.6%
Q1 2011+0.0%
Q4 2010+1.2%
Q3 2010+1.2%
Q2 2010-2.6%
Q1 2009-2.8%
Q1 2010-1.1%
Q2 2009+2.9%
Q4 2007+2.9%
Q4 2009+2.9%
Q3 2009-3.0%
Q3 2008-3.0%
Q4 2008-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro